Medigene receives milestone payment from regeneron pharmaceuticals, inc.

Planegg/martinsried, december 3, 2024. medigene ag (medigene or the “company”, fse: mdg1, prime standard), an oncology platform company focused on the research and development of t cell receptor (tcr)-guided therapies for the treatment of cancer, today announced a usd $1 million milestone payment from regeneron pharmaceuticals, inc. was triggered. regeneron purchased the mage-a4-tcr program as part of its acquisition of 2seventy bio inc.'s pre-clinical and clinical oncology and autoimmune cell therapy pipeline, which closed in april 2024. the payment was triggered by a development milestone for a trial in china led by jw therapeutics (also a prior collaborator of 2seventy bio, inc.) of regeneron's mage-a4 cell therapy, which contains a medigene generated t cell receptor (tcr) targeting mage-a4.
REGN Ratings Summary
REGN Quant Ranking